Larotrectinib treatment for infantile fibrosarcoma in newborns: a case report and literature review

Infantile fibrosarcoma (IFS) is a rare tumor in childhood characterized by a single, localized, painless mass that grows rapidly but has a relatively indolent biological behavior and a favorable prognosis. Eighty-five percent of infantile fibrosarcomas are associated with t (12;15) (p13;25) chromosomal translocation resulting in ETV6-NTRK3 gene fusion, which provides the target for targeted therapy. Here, we report a case of IFS in a newborn with a mass in the left lower extremity confirmed by imaging, histopathological examination, tissue FISH testing, and high-throughput sequencing to detect gene rearrangement. Based on gene fusion targeted drug testing results, the patient was treated with standard doses of larotrectinib, resulting in significant mass shrinkage with no adverse effects, demonstrating the treatment effect of targeted therapy. This case provides a reference for using larotrectinib in newborns with IFS.

[1]  J. L. López Gutiérrez,et al.  Therapeutic strategies and clinical evolution of patients with infantile fibrosarcoma: a unique paediatric case series , 2023, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

[2]  Yue He,et al.  Atypical/unbalanced ETV6/NTRK3 rearrangement in salivary secretory carcinoma with a focus on the incidence, the patterns, and the clinical implications. , 2022, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.

[3]  M. Mandal,et al.  Therapeutic targeting of RBPJ, an upstream regulator of ETV6 gene, abrogates ETV6-NTRK3 fusion gene transformations in glioblastoma. , 2022, Cancer letters.

[4]  K. Pajtler,et al.  Genomic Evolution and Personalized Therapy of an Infantile Fibrosarcoma Harboring an NTRK Oncogenic Fusion , 2022, JCO precision oncology.

[5]  T. Sullivan,et al.  Long term follow-up of congenital infantile fibrosarcoma of the orbital region. , 2022, Orbit.

[6]  J. López-Gutiérrez,et al.  Larotrectinib as an Effective Therapy in Congenital Infantile Fibrosarcoma: Report of Two Cases , 2022, European journal of pediatric surgery reports.

[7]  M. Kotb,et al.  Jejunal infantile fibrosarcoma: An unusual cause of neonatal intestinal obstruction , 2021, Congenital anomalies.

[8]  J. L. López Gutiérrez,et al.  Treatment of infantile fibrosarcoma associated to an abdominal aortic aneurysm with larotrectinib: a case report , 2021, Pediatric hematology and oncology.

[9]  C. Antonescu,et al.  Diagnosis and management of tropomyosin receptor kinase (TRK) fusion sarcomas: expert recommendations from the World Sarcoma Network , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  R. Has,et al.  The Giant Infantile Fibrosarcoma of Fetal Oropharynx and Anterior Neck , 2020, Fetal and pediatric pathology.

[11]  A. Pappo,et al.  A newborn with a large NTRK fusion positive infantile fibrosarcoma successfully treated with larotrectinib , 2020, Pediatric blood & cancer.

[12]  S. DuBois,et al.  The Evolving Diagnostic and Treatment Landscape of NTRK-Fusion-Driven Pediatric Cancers , 2020, Pediatric Drugs.

[13]  S. Bielack,et al.  Rapid, complete and sustained tumour response to the TRK inhibitor larotrectinib in an infant with recurrent, chemotherapy-refractory infantile fibrosarcoma carrying the characteristic ETV6-NTRK3 gene fusion , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  N. Shukla,et al.  Larotrectinib efficacy and safety in pediatric TRK fusion cancer patients. , 2019, Journal of Clinical Oncology.

[15]  Jessica L. Davis,et al.  Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study. , 2018, The Lancet. Oncology.

[16]  M. Harris,et al.  Recurrent EML4–NTRK3 fusions in infantile fibrosarcoma and congenital mesoblastic nephroma suggest a revised testing strategy , 2018, Modern Pathology.

[17]  Funda Meric-Bernstam,et al.  Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children , 2018, The New England journal of medicine.

[18]  R. Craigie,et al.  Congenital infantile fibrosarcoma of the colon: a case series and literature review , 2014, Pediatric Surgery International.

[19]  M. Nikiforova,et al.  ETV6‐NTRK3 is a common chromosomal rearrangement in radiation‐associated thyroid cancer , 2014, Cancer.

[20]  I. Brucknerová,et al.  Unusual cause of neonatal intestinal obstruction , 2012 .

[21]  E. Connolly,et al.  Secretory carcinoma of the breast: results from the survival, epidemiology and end results database. , 2012, Breast.

[22]  G. Webersinke,et al.  Characterization of a newly identified ETV6-NTRK3 fusion transcript in acute myeloid leukemia , 2011, Diagnostic pathology.

[23]  A. Ferrari,et al.  Infantile fibrosarcoma: management based on the European experience. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  F. Enzinger,et al.  Infantile fibrosarcoma , 1976, Cancer.

[25]  Jia-xin Yang,et al.  Ovarian yolk sac tumor in postmenopausal females , 2018, Medicine.

[26]  R. Doebele,et al.  TRKing down an old oncogene in a new era of targeted therapy. , 2015, Cancer discovery.

[27]  A. Waweru,et al.  Chemotherapy induced myelosuppression. , 2007, East African medical journal.

[28]  D. C. Henckel,et al.  Case report. , 1995, Journal.

[29]  S. Siegel,et al.  Problems in the chemotherapy of cancer in the neonate. , 1981, The American journal of pediatric hematology/oncology.

[30]  John H. Jopson,et al.  A REPORT OF TWO CASES , 1902 .